OBJECTIVE: To determine the prognostic value of patient and treatment parameters in osteosarcoma, and whether these are equally important across international boundaries. DESIGN: Retrospective, cross-sectional study of 428 patients diagnosed with around-knee osteosarcoma, between 1990 and 1997 in Birmingham, UK, and Bologna, Italy. Disease-free survival (DFS) and overall survival (OS) assessed by Kaplan-Meier, Fisher's PLSD and Cox proportional hazard regression. RESULTS: Five-year DFS and OS were 56 and 73% at Centre 1, compared to 43 and 60% at Centre 2 (P=0.0022 and P = 0.025, respectively). The most important bad prognostic factors for DFS and OS respectively were raised alkaline phosphatase at diagnosis (P=0.002 and P=0.003), tumour necrosis < 90% following chemotherapy (P=0.001 and P = 0.004) and volume > 150 cm(3) at diagnosis (P=0.04 and P=0.006). The most significant combination of bad prognostic factors was alkaline phosphatase and tumour necrosis. A total of 73% of patients at Centre 1 had greater than 90% necrosis of the tumour following neoadjuvant chemotherapy compared with 29% at Centre 2. CONCLUSIONS: Tumour-based prognostic factors have similar significance across international boundaries. Chemotherapy effectiveness appears to be a major factor in explaining the survival difference between the two centres.
OBJECTIVE: To determine the prognostic value of patient and treatment parameters in osteosarcoma, and whether these are equally important across international boundaries. DESIGN: Retrospective, cross-sectional study of 428 patients diagnosed with around-knee osteosarcoma, between 1990 and 1997 in Birmingham, UK, and Bologna, Italy. Disease-free survival (DFS) and overall survival (OS) assessed by Kaplan-Meier, Fisher's PLSD and Cox proportional hazard regression. RESULTS: Five-year DFS and OS were 56 and 73% at Centre 1, compared to 43 and 60% at Centre 2 (P=0.0022 and P = 0.025, respectively). The most important bad prognostic factors for DFS and OS respectively were raised alkaline phosphatase at diagnosis (P=0.002 and P=0.003), tumour necrosis < 90% following chemotherapy (P=0.001 and P = 0.004) and volume > 150 cm(3) at diagnosis (P=0.04 and P=0.006). The most significant combination of bad prognostic factors was alkaline phosphatase and tumour necrosis. A total of 73% of patients at Centre 1 had greater than 90% necrosis of the tumour following neoadjuvant chemotherapy compared with 29% at Centre 2. CONCLUSIONS: Tumour-based prognostic factors have similar significance across international boundaries. Chemotherapy effectiveness appears to be a major factor in explaining the survival difference between the two centres.
Authors: G Saeter; T Wiebe; T Wiklund; O Monge; Y Wahlqvist; K Engström; E Forestier; T Holmström; A E Stenwig; H Willén; O Brosjö; G Follerås; T A Alvegård; H Strander Journal: Acta Orthop Scand Suppl Date: 1999-06
Authors: G Bacci; S Ferrari; S Lari; M Mercuri; D Donati; A Longhi; C Forni; F Bertoni; M Versari; E Pignotti Journal: J Bone Joint Surg Br Date: 2002-01
Authors: G Bacci; S Ferrari; F Bertoni; P Ruggieri; P Picci; A Longhi; R Casadei; N Fabbri; C Forni; M Versari; M Campanacci Journal: J Clin Oncol Date: 2000-12-15 Impact factor: 44.544
Authors: G Bacci; S Ferrari; M Mercuri; F Bertoni; P Picci; M Manfrini; A Gasbarrini; C Forni; M Cesari; M Campanacci Journal: Acta Orthop Scand Date: 1998-06
Authors: V H Bramwell; M Burgers; R Sneath; R Souhami; A T van Oosterom; P A Voûte; J Rouesse; D Spooner; A W Craft; R Somers Journal: J Clin Oncol Date: 1992-10 Impact factor: 44.544
Authors: L C de Sá Rodrigues; K E Holmes; V Thompson; C M Piskun; S E Lana; M A Newton; T J Stein Journal: Vet Comp Oncol Date: 2015-02-03 Impact factor: 2.613